The PMS and AIF performance from April reflect continued overweight stance on BFSI, pharma, and engineering sectors, while ...

The biosimilars segment, too, will see fresh launches including Bevacizumab in the US, and Semaglutide filings across developed and emerging markets, including India by calendar 2026.

At 11:30 IST, the barometer index, the S&P BSE Sensex dropped 578.57 points or 0.72% to 79,756.24. The Nifty 50 index tumbled 184.85 points or 0.76% to 24,088.95.

The company also reported consolidated revenue of Rs 4,454 crore, reflecting a 15% year-on-year increase on a like-for-like ...

Biocon reported a significant surge in Q4 net profit, up 153% to Rs 344 crore, with revenue growing 12% to Rs 4,454 crore.

Aviations stocks: Shares of Interglobe Aviation Ltd, the parent company of India's largest airline IndiGo, and SpiceJet will ...

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ...

Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar drugs in its key U.S. and European markets.

Today, companies across sectors including Titan Company, L&T, Pidilite Industries, Asian Paints, Britannia Industries, Canara ...

Hey there, job seekers! Get ready to mark your calendars because Career Fest 2025 is coming to shake up your career game!

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara ...